Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.71 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316370 | 0.90 | CYP11B1 (0.69) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL12045347 | 0.86 | HMOX1 (0.84) | CYP19A1HMOX1TBXAS1KMT2A | |
| Hydrochloric Acid SCHEMBL9996059 | 0.84 | HMOX1 (0.81) | CYP19A1HMOX1TBXAS1KMT2A | |
| SCHEMBL19390253 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL11404089 | 0.83 | HMOX1 (0.91) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL2749075 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1TBXAS1 | |
| SCHEMBL20570009 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL3160306 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| Hydrochloric Acid SCHEMBL411704 | 0.81 | CYP19A1 (0.69) | CYP19A1HMOX1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL10492248 | 0.80 | CYP19A1 (0.67) | CYP19A1HMOX1TBXAS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-4006243-A | FUNGICIDE, BACTERICIDE, YEAST | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP19A1 86/4885HMOX1 1247/4885CYP11B1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.